Bergen Bio to present Inhibitor Bemcentinib in Non-Small Cell Lung Cancer World Conference on Lung Cancer (WCLC) in Barcelona

BerGenBio will have two presentations to highlight its Phase II clinical trial with bemcentinib and Merck’s anti-PD-1 therapy Keytruda in patients with advanced non-small cell lung cancer (NSCLC), which showed promising clinical activity overall.

As the company announced in June, the promising clinical activity was particularly shown in patients with AXL positive tumours, including those with low or no PD-L1 expression. Preliminary median overall survival has reported 12.2 months, surpassing historical benchmarks in second-line treatment with PD-1 inhibitor monotherapy, especially in low PD-L1 patients; and the combination treatment was well-tolerated.

The company said it will also present details of a second cohort of the Phase II trial (BGB008, NCT03184571) at a poster session, entitled: A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1. The trial has been expanded to include patients that have been previously treated with a PD-(L)1 inhibitor, or a PD-(L)1 inhibitor in combination with platinum containing chemotherapy and will further evaluate the clinical activity and safety profile of the combination.